Sending Office: Honorable Brian Higgins
Become an Original Cosponsor of the Cancer Drug Coverage Parity Act
Over 175 bipartisan members in the 115th Congress supported legislation to ensure cancer patients have access to life-saving drug treatments
*The deadline for original cosponsors is COB TODAY, March 12*
116th Cosponsors: Guthrie, Matsui, Bilirakis, Kilmer, Fitzpatrick, King, Nadler, DeFazio, Hastings, Olson, Wasserman Schultz, Hurd, Bera, Cole, Khanna, McCaul, Norton
115th Cosponsors: Higgins, Adams, Amodei, Bacon, Bera, Bergman, Biggs, Bilirakis, Bishop, Black, Blackburn, Blumenauer, Bonamici, Boyle, Brady, Brooks, Bucshon, Bustos, Carter, Cartwright, Chu, Clark, Clarke, Cleaver,
Coffman, Cohen, Collins (Doug), Comstock, Connolly, Costello, Cramer, Culberson, Cummings, Davis, DeFazio, Delaney, DeLauro, Dent, DeSaulnier, DesJarlais, Deutch, Donovan, Doyle, Duffy, Engel, Eshoo, Evans, Ferguson, Fitzpatrick, Flores, Fortenberry, Foster,
Frankel, Frelinghuysen, Gallagher, Gallego, Garamendi, Gianforte, Gonzalez, Gonzalez-Colon, Gowdy, Graves, Griffith, Grijalva, Grothman, Guthrie, Gutierrez, Hanabusa, Harper, Hartzler, Hastings, Hice, Higgins (Clay), Himes, Hudson, Huffman, Hultgren, Jackson
Lee, Jayapal, Johnson (Bill), Jones, Joyce, Katko, Keating, Kelly, Kennedy, Khanna, Kihuen, Kildee, Kilmer, King (Pete), Lance, Langevin, Larson, Latta, Lawrence, Lewis, Lieu, Lipinski, Loebsack, Lofgren, Long, Loudermilk, Luetkemeyer, Lujan, Lujan Grisham,
Lynch, MacArthur, Maloney (Carolyn B.), Maloney (Sean Patrick), Mast, Matsui, McCaul, McCollum, McGovern, McKinley, McMorris Rodgers, Mitchell, Moulton, Murphy (Stephanie), Murphy (Tim), Napolitano, Norman, Norton, O’Halleran, O’Rourke, Olson, Palazzo, Panetta,
Payne, Peters, Pingee, Pocan, Poe, Poliquin, Price, Raskin, Reichert, Renacci, Rice, Ros-Lehtinen, Roybal-Allard, Rush, Rutherford, Ryan (Tim), Sarbanes, Schiff, Schneider, Scott (Austin), Sensenbrenner, Sessions, Shea-Porter, Slaughter, Smith, Smucker, Speier,
Stefanik, Stivers, Suozzi, Swalwell, Takano, Thompson, Tipton, Tonko, Trott, Turner, Upton, Walberg, Walz, Wasserman-Schultz, Wittman, Yarmuth, Yoder, Yoho, Young (David), Young (Don)
Supporting Organizations include: AIM at Melanoma, American Cancer Society Cancer Action Network, American Society of Hematology, American Society of Clinical Oncology, Aplastic Anemia and MDS International Foundation,
Association of Community Cancer Centers, Association of American Cancer Institutes, Astellas Pharma US, Cancer Support Community, Celgene, Community Oncology Alliance, Dana Farber Cancer Institute, Debbie’s Dream Foundation: Curing Stomach Cancer, Facing Our
Risk of Cancer Empowered (FORCE), Fight Colorectal Cancer, Genentech, Inc., Glaxo Smith Kline, Hematology/Oncology Pharmacy Association, International Myeloma Foundation, Karmanos Cancer Institute, Leukemia & Lymphoma Society, Lymphoma Research Foundation,
National Brain Tumor Society, National Patient Advocate Foundation, Oncology Nursing Society, Ovarian Cancer National Alliance, Patient Services, Inc., Roswell Park Cancer Institute, Susan G. Komen, Takeda Oncology, The Ohio State University Comprehensive
Cancer Center – James Cancer Center and Richard J Solove Institute, Zero – The End of Prostate Cancer, Patients Equal Access Coalition
Insurance coverage for cancer treatments has not kept up with some of the most promising oncology research, and cancer patients are paying the price. The
Cancer Drug Coverage Parity Act would require health insurance plans that cover traditional intravenous/injectable chemotherapy to provide no less favorable coverage for prescribed, orally-administered anticancer medications.
Oral chemotherapy is becoming a common standard of care for patients with many types of cancer. And more treatments are on the way as oral chemo represents approximately 35% of the oncology development pipeline. Most of these medications are irreplaceable
as no alternative intravenous/injectable agents exist, leaving patients with the burden of paying astronomical out-of-pocket costs or forgoing treatment.
Yet despite the fact that oral chemotherapy is popular with oncologists and patients, this legislation is needed because health insurance coverage for different types of cancer treatments often is not uniform. While intravenous treatments are usually covered
under a plan’s medical benefit component, orally-administered anti-cancer medications are covered under a plan’s prescription drug component which often places a higher percentage of cost-sharing on the patient.
This considerable disparity in coverage can leave cancer patients to make difficult decisions on what type of care they will receive based on the outdated guidelines of their health insurance policy, rather than the advice of their doctor. Studies have consistently
shown that, when faced with high co-pays for orally administered anti-cancer drugs, some patients choose to simply not fill a prescription. Ensuring parity in coverage would both increase access to life-saving treatments and improve the quality of life for
While America continues to set an example for the world in biomedical research, Americans will struggle to gain access to these new discoveries if insurance coverage does not keep up with the science. This legislation prepares us for the next generation
of cancer treatments.
For more information or to become a cosponsor of the Cancer Drug Coverage Parity Act, please contact Jessica Burnell (Jessica.Burnell@mail.house.gov) in Rep. Higgins’s office or Sophie Trainor
(Sophie.Trainor@mail.house.gov) in Rep. Guthrie’s office. Thank you.
Brian Higgins Brett Guthrie
Member of Congress Member of Congress
Doris Matsui Gus M. Bilirakis
Member of Congress Member of Congress
e-Dear Colleague version 2.0